Acrux Limited : Marketing approval granted for Ellavie in Switzerland
01/30/2012 | 02:03am
ACRUX (ACR) - ASX ANNOUNCEMENT 30 JANUARY 2012
MARKETING APPROVAL GRANTED FOR ELLAVIE™
IN SWITZERLAND
Acrux (ASX: ACR) announced today that Swissmedic, the Swiss
agency for therapeutic products, has granted a marketing
authorisation in Switzerland for Ellavie™, Acrux's estradiol
spray for treating menopause symptoms.
Acrux's estradiol spray is approved for marketing in the
United States and Sweden, with marketing applications under
review by regulatory authorities in South Korea and South
Africa. The approval in Sweden enables Acrux to seek
marketing approvals in other European countries under a
Mutual Recognition Procedure.
Acrux is currently engaged in commercial discussions with
potential marketing and manufacturing partners for the
estradiol spray in the European Union and in Eastern
Europe.
"We are delighted that our marketing partner in Switzerland
has achieved approval for Ellavie. We expect to advance the
commercialisation of our estradiol spray product in the
broader European market through further partnerships." said
Acrux CEO Richard Treagus.
The estrogen therapy market outside the USA is valued at
US$360 million per annum. In Europe, transdermal therapies
(skin patches and gels) account for approximately half of the
estrogen therapy market.
Contact
Richard Treagus, CEO: 0417 520 509
About Acrux www.acrux.com.au
